VALN — Valneva SE

Is VALN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Valneva SE (VALN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $6.87. The rating moved from Neutral to Overbought on August 5, 2026.

See all overbought Healthcare stocks →

AI analysis

Valneva SE (VALN) is a vaccine-focused biotech with manufacturing strengths and a small pipeline that creates both strategic optionality and binary clinical/regulatory risks. The company's limited commercial track record and periodic contract uncertainty make near-term revenue volatile and increase reliance on partnerships, milestone payments, or additional financing. Potential upside derives from successful late-stage readouts, new supply/partner agreements, or stronger commercial uptake of approved products; downside is driven by clinical setbacks, contract losses, and balance-sheet pressure. Given current market tone mildly favoring risk assets, short-term flows could be supportive, but sustainable appreciation depends on clearer revenue visibility and funding stability.

Key factors

  • Vaccine-focused business model with a small but differentiated pipeline in prophylactic vaccines (historical assets include inactivated and specialized vaccine candidates)
  • Manufacturing capabilities and fill/finish experience that can be monetized via partnerships or contract manufacturing
  • Limited and uneven commercial revenue history leading to sensitivity to single-contract outcomes and seasonal demand
  • Balance sheet and cash runway issues that increase reliance on partnerships, milestone payments, or capital raises
  • Regulatory and clinical binary events (approvals, trial readouts) that can produce material share-price moves
  • Macro risk-on posture in equities could provide near-term supportive flows into small-cap biotechs, but sustained outperformance requires visible commercial traction

Risks

  • Clinical or regulatory setbacks for vaccine candidates leading to delayed approvals or withdrawals
  • Loss or non-renewal of supply contracts and prior contract disputes reduce near-term revenue visibility
  • High cash burn and potential need for dilution through equity raises or costly debt
  • Competition from larger vaccine and biologics players with deeper commercial and distribution footprints
  • Market sensitivity to broader biotech sentiment and macro moves (rates, risk appetite) which can amplify volatility
  • Manufacturing or supply-chain disruptions that impair ability to meet partner or government commitments

See today's live rating, score and targets

Members see the live hourly rating for VALN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.